Caspase-6, a member of the cysteine protease family, is well characterized for its role in programmed cell death (PCD), where it acts primarily as an executioner caspase. Many studies, as recently reviewed by Graham et. al. in Trends in Neurosciences, have revealed Caspase-6 as a possible contributor to neurodegenerative pathology associated with Huntington’s Disease (HD), Alzheimer’s Disease (AD), aging, and stroke. Although the mechanisms behind the role of caspase-6 mediated neurodegeneration are still being defined, evidence suggests activation of caspase-6, and resulting cleavage of defined caspase-6 substrates such as Huntingtin, Amyloid Precursor Protein (APP), Tau, CBP/p300, NF-kB, and Caspase-8, make inhibition of caspase-6 an intriguing therapeutic target for neurodegenerative disease.
Enzo Life Sciences offers a wide range of products for Caspase-6 research, including high-purity active recombinant enzymes, substrates, and inhibitors.